This paper was presented on June 4, 2018 at the Boston Bio Conference. It discusses the effectiveness of their drug ZEN 3694 in hindering or eliminating the ability of the cancer to develop a resistance to Xtandi. Check out the initial results of the testing, particularly the Phase 2a Enzalutamide combo trial graph on Slide 17. The Cohort 2 group had the high dosage of Zen 3694 and 3 of them have had no disease progression in 60 to 64 weeks. Note that the study does not say what drug or dosage Cohort 2 had but take my word for it.
The webcast link is towards the bottom of the page. You will have to register.
CALGARY, Alberta, June 04, 2018 (GLOBE NEWSWIRE) -- Zenith Capital Corp. ("Zenith" or the "Company") today announced that its wholly owned subsidiary, Zenith Epigenetics Ltd. ("Zenith Epigenetics"), has initiated the Phase 2 portion of the ongoing metastatic Castration Resistant Prostate Cancer ("mCRPC") clinical trial in patients that have progressed on an androgen receptor antagonist (ARi). In Phase 2, Zenith Epigenetics will be focused on continuing the evaluation of efficacy of ZEN-3694 in combination with enzalutamide (Xtandi). The associated translational program, measuring target modulation, measuring effect of ZEN-3694 on resistance markers of ARi, and for identifying patients that benefit the most from the combination treatment, will provide valuable information for further clinical development. Clinical data to date show that ZEN-3694 is active, safe, and well differentiated and will be presented at an upcoming scientific meeting.
Based on the continuous clinical success and strong pre-clinical rationale, Zenith Epigenetics is also expanding its clinical program. "We are excited as this clinical trial continues to deliver good results strengthening our confidence in ZEN-3694 and the clinical program. We are diligently expanding the clinical program into other patient populations with significant unmet need and poor prognosis. We believe we have a differentiated asset and we are a leader in combination approach with BET inhibitors,” stated Mr. Donald McCaffrey, President and Chief Executive Officer.
Additional trial details and updates can be found at: clinicaltrials.gov/.
Private Placement
The Company also announced that it intends to complete an equity private placement of up to 10 million common shares (the “Offering”). The net proceeds of the Offering will be used to fund research and development activities, general and administrative expenses, working capital and other general corporate purposes. Investment will be restricted to qualified Investors only on a first subscribed basis.
Webcast Presentation at the 2018 BIO International Convention
The Company will also host a Webcast today as part of its participation in the 2018 BIO International Convention in Boston, MA. Mr. McCaffrey will provide a corporate update and overview of recent activities.
Presentation & Webcast Details:
Date: Monday, June 4, 2018
Time: 2:30 pm EDT
Duration: ~13 minutes
Location: Boston Convention & Exhibition Center, Theater 2
Webcast Link: veracast.com/webcasts/bio/i...
An archived replay of the webcast will also be available on the Company’s website under the EVENTS section.
Check out the P
Scot inhibition study 
ADT and Dementia Link Study
Study I am qualified for
Benefits of Testosterone Proven in Pilot Study
Radiation therapy for METS study 
